TransMedics is executing a strategic debt-funded capacity expansion, with total debt rising from $518.3M in 2024Q4 to $867.7M in 2026Q2 and PPE surging to $702.9M, positioning for long-term organ transplant volume growth.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.51+71.4% vs $0.30 | $203M+14.0% vs $178M |
Q3 2026 Aug 4, 2026 | $0.44-11.2% vs $0.50 | $190M+3.2% vs $184M |
Q2 2026 May 5, 2026 | $0.30-51.6% vs $0.62 | $174M-0.3% vs $174M |
Q1 2026 Feb 24, 2026 | $0.57+39.0% vs $0.41 | $161M+3.5% vs $155M |
TransMedics Group NASDAQ: TMDX raised its full-year revenue outlook after reporting record third-quarter revenue and transplant case volume, as gains in its liver and heart businesses helped offset a decline in U.S. deceased donor volume.
Three stocks are seeing unusual options activity following their quarterly earnings reports: DraftKings Inc (NASDAQ:DKNG), TransMedics Group Inc (NASDAQ:TMDX), and Omada Health Inc (NASDAQ:OMDA).
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript
Benchmark TMDX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for TransMedics Group, Inc. (TMDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $88.24 | $3.05B | 24.94 | 37.13% | 19.85% | 28.38% | — | |
| $1.15 | $106.57M | -4.37 | — | — | -21.11% | — | |
| $13.57 | $3.7B | 23.79 | 3.21% | 11.24% | 9.07% | 0.43% | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $89.99 | $4.94B | 26.34 | 10.74% | 13.01% | 15.35% | — | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — |
TransMedics Group, Inc. (TMDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
TransMedics Group, Inc. (TMDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
May 21, 2026·SEC
May 5, 2026·SEC
Get notified when TMDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TransMedics Group, Inc. (TMDX) stock FAQ — growth, dividends, profitability & financials explained
TransMedics Group, Inc. (TMDX) reported $727.6M in revenue over the trailing twelve months. Revenue was $605.5M in fiscal year 2025. That is 9652% more than the $6.2M of fiscal year 2016.
TransMedics Group, Inc. (TMDX) grew revenue by 28.5% over the trailing twelve months, compared with the twelve months before.
Yes. TransMedics Group, Inc. (TMDX) earned $144.5M in net income over the trailing twelve months (a 19.9% net margin).
TransMedics Group, Inc. (TMDX) had a return on equity (ROE) of 28.4% over the trailing twelve months. That is well above the market's typical 10-15%.
TransMedics Group, Inc. (TMDX) generated $44.7M in free cash flow over the trailing twelve months.
